Nektar Therapeutics
NASDAQ:NKTR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.42
1.83
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NKTR stock under the Base Case scenario is 0.692 USD. Compared to the current market price of 1.205 USD, Nektar Therapeutics is Overvalued by 43%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Nektar Therapeutics
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NKTR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Nektar Therapeutics
Balance Sheet Decomposition
Nektar Therapeutics
Current Assets | 295.2m |
Cash & Short-Term Investments | 271.2m |
Receivables | 1.2m |
Other Current Assets | 22.8m |
Non-Current Assets | 48.1m |
Long-Term Investments | 19.4m |
PP&E | 24.4m |
Other Non-Current Assets | 4.3m |
Current Liabilities | 57.3m |
Accounts Payable | 6.5m |
Accrued Liabilities | 50.9m |
Non-Current Liabilities | 206.3m |
Other Non-Current Liabilities | 206.3m |
Earnings Waterfall
Nektar Therapeutics
Revenue
|
93.1m
USD
|
Cost of Revenue
|
-38m
USD
|
Gross Profit
|
55.2m
USD
|
Operating Expenses
|
-190.3m
USD
|
Operating Income
|
-135.1m
USD
|
Other Expenses
|
-41.9m
USD
|
Net Income
|
-177m
USD
|
Free Cash Flow Analysis
Nektar Therapeutics
USD | |
Free Cash Flow | USD |
NKTR Profitability Score
Profitability Due Diligence
Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Nektar Therapeutics's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
NKTR Solvency Score
Solvency Due Diligence
Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Nektar Therapeutics's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NKTR Price Targets Summary
Nektar Therapeutics
According to Wall Street analysts, the average 1-year price target for NKTR is 2.703 USD with a low forecast of 1.313 USD and a high forecast of 4.2 USD.
Dividends
Current shareholder yield for NKTR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Contact
IPO
Employees
Officers
The intrinsic value of one NKTR stock under the Base Case scenario is 0.692 USD.
Compared to the current market price of 1.205 USD, Nektar Therapeutics is Overvalued by 43%.